share_log

8-K: Current report

8-K: Current report

8-K：重大事件
美股SEC公告 ·  2024/08/07 05:11

Moomoo AI 已提取核心訊息

BeiGene reported strong Q2 2024 results with total revenue of $929 million, up 56% year-over-year, driven by BRUKINSA sales growth. The company achieved non-GAAP operating income of $48 million, a key milestone in its path to profitability.BRUKINSA global sales reached $637 million, up 107% year-over-year, with U.S. sales of $479 million (+114%) and European sales of $81 million (+209%). BeiGene advanced its hematology pipeline, including sonrotoclax (BCL2 inhibitor) and BGB-16673 (BTK degrader). The solid tumor pipeline progressed with multiple candidates in lung, breast, and GI cancers.The company opened an $800 million biologics manufacturing facility in New Jersey and proposed redomiciling to Switzerland to strengthen its global presence. BeiGene maintained financial discipline, reducing GAAP operating loss by 66% to $107 million and improving cash used in operations to $96 million from $294 million in Q2 2023.
BeiGene reported strong Q2 2024 results with total revenue of $929 million, up 56% year-over-year, driven by BRUKINSA sales growth. The company achieved non-GAAP operating income of $48 million, a key milestone in its path to profitability.BRUKINSA global sales reached $637 million, up 107% year-over-year, with U.S. sales of $479 million (+114%) and European sales of $81 million (+209%). BeiGene advanced its hematology pipeline, including sonrotoclax (BCL2 inhibitor) and BGB-16673 (BTK degrader). The solid tumor pipeline progressed with multiple candidates in lung, breast, and GI cancers.The company opened an $800 million biologics manufacturing facility in New Jersey and proposed redomiciling to Switzerland to strengthen its global presence. BeiGene maintained financial discipline, reducing GAAP operating loss by 66% to $107 million and improving cash used in operations to $96 million from $294 million in Q2 2023.
百濟神州在2024年第二季度報告了強勁的業績，總營業收入爲92900萬，同比增長56%，主要得益於BRUKINSA的銷售增長。公司實現了4800萬的非公認會計原則運營收入，這是其盈利之路上的一個重要里程碑。BRUKINSA全球銷售額達到63700萬，同比增長107%，其中美國銷售額爲47900萬（+114%），歐洲銷售額爲8100萬（+209%）。百濟神州在其血液學產品線方面取得了進展，包括sonrotoclax（BCL2抑制劑）和BGb-16673（BTk降解劑）。固體腫瘤產品線也取得了進展，涉及多種候選藥物用於肺癌、乳腺癌和胃腸道癌症。公司在新澤西州開設了一座80000萬的生物製品製造設施，並提議遷回瑞士，以增強其全球業務。百濟神州保持了財務紀律，降低了66%的公認會計原則運營虧損至10700萬，並將運營中使用的現金從2023年第二季度的29400萬改善至9600萬。
百濟神州在2024年第二季度報告了強勁的業績，總營業收入爲92900萬，同比增長56%，主要得益於BRUKINSA的銷售增長。公司實現了4800萬的非公認會計原則運營收入，這是其盈利之路上的一個重要里程碑。BRUKINSA全球銷售額達到63700萬，同比增長107%，其中美國銷售額爲47900萬（+114%），歐洲銷售額爲8100萬（+209%）。百濟神州在其血液學產品線方面取得了進展，包括sonrotoclax（BCL2抑制劑）和BGb-16673（BTk降解劑）。固體腫瘤產品線也取得了進展，涉及多種候選藥物用於肺癌、乳腺癌和胃腸道癌症。公司在新澤西州開設了一座80000萬的生物製品製造設施，並提議遷回瑞士，以增強其全球業務。百濟神州保持了財務紀律，降低了66%的公認會計原則運營虧損至10700萬，並將運營中使用的現金從2023年第二季度的29400萬改善至9600萬。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間